Anthropic Launches IPO Roadshow: 825 Million Shares at $70 to $78
Anthropic launched its IPO roadshow on 10 November, setting a price range of $70 to $78 per share for 825 million shares — $57.75 billion to $64.35 billion in total — with pricing expected on 18 November and Nasdaq trading on 19 November.

First, the boundary: Anthropic going public is not itself the news. The site already covered that in October with "From Confidential Draft to Public Prospectus: Anthropic Files Its S-1, Plans to List on Nasdaq as ANT," about the public filing on October 26, when the share count and price were still blank. The new event on November 10 is the launch of the roadshow: Anthropic announced on its website that day that it had started the roadshow for its proposed initial public offering, giving a price range for the first time — $70 to $78 per share — and a share count — 825 million shares. The primary sources are Anthropic's own announcement (Published: 2026-11-10) and Amendment No. 2 to its Form S-1 filed with the U.S. Securities and Exchange Commission the same day. The pricing and listing dates were first reported by CNBC citing people familiar with the plans, and confirmed in the FAQ on Anthropic's IPO website on November 12; the sourcing is flagged wherever those dates appear below.
What was set: 825 million shares at $70 to $78 each
Anthropic's November 10 announcement is short, and its core is four sentences. First, the proposed offering is 825,000,000 shares of Class A common stock, of which 801,351,354 shares are being offered by Anthropic and 23,648,646 shares by existing stockholders; the company receives no proceeds from the selling stockholders' shares. Second, the underwriters have a 30-day option to buy up to an additional 123,750,000 shares. Third, the initial public offering price is expected to be between $70.00 and $78.00 per share, and the company has applied to list on the Nasdaq Global Select Market under the symbol ANT. Fourth, copies of the prospectus can be obtained from Goldman Sachs and Morgan Stanley — the joint lead underwriters of the offering.
The final paragraph of the announcement is boilerplate legal language, but it matters for readers: a registration statement has been filed with the SEC but has not yet become effective; until it is effective, the shares may not be sold and offers to buy may not be accepted; and the announcement itself is not an offer to sell. In plain terms: the price range is out, the share count is out, but the deal is not done — whether it happens, and at what price, depends on the SEC and on pricing after the roadshow. That is what a roadshow is for: the company and its bankers take the prospectus to investors, pitch the deal, and find out what price the market will pay.
One detail is easy to miss: of the 825 million shares, about 97% are new shares from the company and only about 3% are being sold by existing stockholders. Existing holders selling is normal, but the split says this deal is mostly the company raising money, not early investors cashing out. The seven co-founders are each selling about 3.4 million shares, according to press reports tracking the deal — a small slice of an 825-million-share offering.
What a roadshow actually does: November 10 to November 19
A roadshow sounds like a tour, and in a way it is: a week of back-to-back sales meetings. Anthropic's management and its underwriters take the prospectus from one institutional investor to the next — presenting the business, walking through the numbers, answering hard questions — and sounding out what price investors are willing to pay. The $70 to $78 range is an opening ask, not a final price; the final price is set only after the roadshow, once the order book is built.
The timetable is now the company's own word: the FAQ on Anthropic's IPO website says the roadshow starts November 10, the final IPO price is expected to be set on November 18, and shares are expected to begin trading on Nasdaq on November 19. CNBC first reported both dates citing people familiar with the plans; on November 12 the company's website put the timetable in its public FAQ, moving it from "reported" to "confirmed by the company." The word "expected" still applies: if the registration statement does not go effective, or regulators do not clear the deal, the dates can slip.
For ordinary investors who want in, the route is also spelled out in the same FAQ: request shares through a participating brokerage platform, which confirms eligibility; there is no guarantee of receiving any shares, or all the shares requested. In other words, institutions are the main audience of the roadshow; retail investors queue outside and wait for their broker to allocate.
There is one more date, 30 days out: the underwriters' option to buy extra shares runs for 30 days. If the stock holds up after listing, the underwriters can buy another 123,750,000 shares at the offer price; if it falls below the offer price, they typically use the option to buy shares in the market and support the price. That is the real purpose of the "greenshoe" — not to sell more stock for profit, but to give the share price a cushion in its first weeks.
Doing the math: $57.75 billion to $64.35 billion raised, and two different valuations
Here is the arithmetic from the announcement's numbers. At the bottom of the range, $70, 825 million shares raise $57.75 billion in total; at the top, $78, they raise $64.35 billion. Split out: the company's new 801,351,354 shares raise $56.09 billion at $70 and $62.51 billion at $78; the selling stockholders' 23,648,646 shares bring in $1.66 billion at $70 and $1.84 billion at $78. If the underwriters exercise their option for another 123,750,000 shares, that adds $9.65 billion at $78, taking the whole deal to about $74.0 billion at most.

Valuation is a different number, and it is easy to mix up. Two figures are circulating in press coverage: the Financial Times puts the fully diluted valuation at about $1.4 trillion, while Dealroom calculates an equity value of about $1.02 trillion at $78, based on roughly 13.09 billion shares outstanding after the offering. Both are correct — they measure different things. The fully diluted figure counts options and restricted stock that have not been issued yet; equity value counts only shares already issued. When reading a headline, ask first which measure it uses before comparing numbers — otherwise it is apples and oranges.
Another set of numbers comes from the business section of the prospectus: run-rate revenue was about $81 billion on October 31, up from about $71 billion at the end of September, according to the Financial Times' reporting on the filing. A $10 billion jump in annualized revenue in one month is exactly the story investors want to hear during a roadshow — but "run-rate" means the most recent month's revenue multiplied by twelve, not revenue already earned in a year. The revenue figures in the prospectus are unaudited interim numbers, as the announcement itself notes.
Against the October S-1: what is actually new this time
The public prospectus of October 26 was remarkable mostly for what it left blank: no share count, no price range, just the plan to list under the ticker ANT. The November 10 amendment fills in the blanks: 825,000,000 shares, $70 to $78, the split between new and selling shares, and the underwriters' option. The two documents are only two weeks apart, but for investors the difference is between "knowing it plans to list" and "being able to calculate what it is worth."
The amendment also refreshes the business numbers. The roadshow materials put third-quarter figures at: revenue of $17.0 billion, year-on-year growth of more than 12x, more than 11,900 customers with at least $100,000 in trailing-twelve-month revenue, and an adjusted operating margin of 15%. The net loss was $23.3 billion, but $21.9 billion of that was a non-cash charge tied to changes in the fair value of convertible notes, derivative liabilities, and SAFEs — not cash burned by the business. One footnote: Reuters reported third-quarter revenue of $16.8 billion in October, while the roadshow materials say $17.0 billion. The gap is small and most likely comes down to rounding or a difference in definitions; the two figures are not worth arguing over.
There was also a small episode on the eve of the roadshow, worth mentioning because it explains why some reports on the evening of November 9 said "$70 to $80." According to Dealroom, late on November 9 Anthropic emailed bankers a draft showing about 867 million shares at $70 to $80; the company then said those pricing details were inaccurate. The filed document says 825 million shares at $70 to $78. When following IPO news, keep drafts and filings apart: one is a number from the negotiating table, the other is the number submitted to the SEC.
$26 billion concurrent private placement: suppliers become shareholders
Separate from the public offering, the prospectus discloses a $26 billion concurrent private placement: Google, Nvidia, AMD, Broadcom, Micron, Microsoft, and TSMC have agreed to buy a combined $26 billion of non-voting Class N shares at the IPO price, according to Dealroom and Al Jazeera citing Reuters. That money is not part of the $57.75 billion to $64.35 billion public raise — it is a separate deal.
The placement deserves its own mention because it is really about Anthropic's supply chain. The buyer list is the company's chip and cloud supplier list: Nvidia, AMD, Broadcom, and Micron supply chips, TSMC makes them, and Google and Microsoft supply cloud. Suppliers putting real money into the company's stock turns a "supply relationship" into a "shareholder relationship." For Anthropic, the benefit is locked-in capacity and partnership; for the suppliers, it is a share in their customer's growth. How much each of the seven is buying was not disclosed individually; only the total is public.
One more detail: the placement buys non-voting Class N shares. The seven suppliers put up money but get no votes — no board seats, no say in governance. That fits Anthropic's structure: it is a public benefit corporation whose charter requires it to pursue the public interest alongside profit, and on October 18 it announced it would commit part of its shares to the newly created Anthropic Public Benefit Fund, with the fund's stake growing as the company grows. Suppliers as shareholders, but not as owners — that arrangement is consistent with the public benefit setup.
How hot is demand: bankers are considering pricing above $78
On the second day of the roadshow, the Financial Times reported on November 11 that demand was strong out of the gate and bankers were considering pricing the IPO above $78, which could push the valuation to $1.5 trillion or more. Bloomberg reported on November 12, via Reuters, that orders were about six times the shares available, and that bankers told investors they would prioritize existing supporters. Both are "people familiar with the matter" reports, not company announcements — Anthropic has confirmed no price above $78 and published no order multiple. They are included here to describe the mood of the roadshow's first two days, not to predict the final price.
The timetable is now the company's own word: the FAQ on Anthropic's IPO website says the final price is expected to be set on November 18 and trading is expected to begin on November 19. CNBC first reported both dates citing people familiar with the plans, and the company's website confirmed the timetable on November 12. The November 10 announcement itself gave no pricing or listing date — only that "the roadshow starts today." During a roadshow the price range, share count, and timetable can all still change; the prospectus is a preliminary one, not the final version. Anyone following this deal should watch for announcements around November 18; until then, every number is an "expected" one.
One caution is worth stating alongside the hot demand: a high order multiple does not mean the stock will rise after listing. Roadshow orders are indications of interest, not completed purchases; prioritizing existing supporters means retail and new investors may receive very little; and a six-times oversubscription sounds hot, but pricing above the top of the range and then falling on the first day of trading has happened before. The heat is real; how long it lasts is unknown.
The biggest IPO ever? Measuring it against Saudi Aramco and Alibaba
Where does $57.75 billion to $64.35 billion sit in IPO history? For reference: Saudi Aramco's 2019 listing raised about $25.6 billion, the largest IPO on record; Alibaba's 2014 New York listing raised about $25 billion, just behind it; Rivian's 2021 listing, at about $13.7 billion, was the big recent tech name. Anthropic at the bottom of its range, $57.75 billion, is already more than twice the Aramco record; at the top, $64.35 billion, it is about two and a half times it. If the greenshoe is fully exercised and the deal reaches roughly $74 billion, the gap grows further.
But "biggest" needs two qualifications. First, the record is about the amount raised in a single offering, not the size of the company: at $78 a share on a fully diluted basis, Anthropic is valued at roughly $1.4 trillion, still well below Aramco's roughly $1.7 trillion market value at listing — raising more money does not mean being a bigger company. Second, the comparison is in nominal dollars, with no inflation adjustment: $25 billion in 2014 and $57.75 billion in 2026 are not the same purchasing power. The record is a nominal figure, useful as a reference point in the news; a serious comparison also looks at valuation, multiples, and the raise as a share of the company's market value.
One more caution on the numbers: the $26 billion concurrent private placement is not part of the public raise. Adding the two together, Anthropic is taking in $83.7 billion to $90.35 billion in this round (the public $57.75 billion to $64.35 billion plus the $26 billion private placement; up to roughly $100 billion if the greenshoe is fully exercised). But the private money comes from seven suppliers, and it is a different kind of money from a public offering — the two should not simply be added together and then compared with the historical record. The public record figure is the $57.75 billion to $64.35 billion itself.
Why can an AI company founded less than five years ago raise at this scale? The answer is in the prospectus numbers: $81 billion of annualized revenue, $17 billion of third-quarter revenue growing more than 12 times year on year, and a 15% adjusted operating margin. The market is pricing in a bet that "selling models" is a business that already works and is still accelerating. The record is also pressure in the other direction: having raised the most money in IPO history means the market's growth expectations are the highest in IPO history too, and every quarterly report after listing will be judged against that number.
One more number is worth calculating on its own: the 825 million shares being sold publicly are about 6.3% of the roughly 13.09 billion shares outstanding after the offering. In other words, Anthropic is raising the most money in IPO history while selling only about 6% of the company. A small free float plus hot demand is a combination that usually means a volatile first few days of trading: few people hold the stock, many want to buy it, the price can spike sharply at the open and fall back just as fast when the excitement fades. No matter how many times oversubscribed the book is during the roadshow, what sets the price after listing is the real buying and selling day by day — and that 6.3% figure is a key to reading the first day of trading.
What it means for developers: the company behind Claude is about to become a public company
For developers who use Claude to write code every day, the most direct effect of Anthropic going public is not the share price — it is information. From the listing day onward, Anthropic will have to publish quarterly financials: how much revenue, how much cost, how much was spent on compute, and how subscriptions and API revenue split. These numbers used to surface only occasionally in a prospectus; after listing, they will arrive every quarter. For questions like "will Claude get more expensive," "will the API be throttled," or "will the small models be cut," financial statements are a far more reliable source than rumors.
The second effect is pressure. A public company has to explain its growth to the market every quarter, and Anthropic's growth story is built on speed like "$10 billion of annualized revenue in a single month." Whether that speed can be sustained will shape product trade-offs: pushing pricier plans more aggressively, moving enterprise customers from the API to more expensive managed services — or, in the other direction, subsidizing prices to protect growth. All of that is speculation; the company has said nothing of the sort. The point is that after listing, the product's business logic gains an extra layer of constraint — the quarterly earnings report — not that a price rise is certain.
The third effect is a test of the public benefit structure. Anthropic's charter requires it to pursue the public interest, and in October it committed part of its shares to the Public Benefit Fund. After listing, that structure faces the open market: will shareholders press it to drop public benefit goals in pursuit of profit? Will the fund's stake grow as promised? Those answers are not in the prospectus; they will emerge from the company's governance over the years after listing. For developers who care about AI safety, that is worth watching longer than any pricing number.
One final judgment: Anthropic's roadshow is a watershed for the AI industry — the first company whose main business is large models has reached the door of the public market, and it arrives with one of the largest fundraisings in history. It says the market believes "selling models can make money" — at least on Anthropic's books. Whether that money buys better models, steadier service, and cheaper prices is a question only the years after listing can answer. Pricing on November 18, trading on November 19 — that is the timetable on the company's own website. We will see then.
Comments (0)
Sources
Related articles
On 20 November 2026, OpenAI released MedChemBench: 99 medicinal-chemistry problems from 117 papers and patents, covering 761 molecules. GPT-6.2 Astra scores 84.5% overall — but 95.4% on assembling structures and only 50.4% on choosing compounds. The total flatters; the components tell the truth.
On 20 November 2026, Thinking Machines Lab released Inkling 2 Mini: a 26.4B-parameter looped transformer that runs its middle 12 layers three times per token, fits in about 20GB, and runs offline on a laptop. It leads open-weights models of its size on DeepSWE and SWE-bench Verified — with the caveats printed in the same announcement.
On 18 November 2026, Google Research and co-authors posted BuggyMLE to arXiv: bugs injected into 222 working ML repositories, and 14 models slide from 95% on the easiest tier to 9% on the hardest. A 9-billion-parameter model trained easy-to-hard beats Claude Opus 5.5 on the 10-bug tier.